¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Polyneuropathy due to other toxic agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polyneuropathy
    ¿©·¯½Å°æº´(Áõ), ´Ù¹ß½Å°æº´(Áõ)
  • paraneoplastic polyneuropathy
    ½Å»ý¹°µþ¸²¿©·¯½Å°æº´(Áõ), ½Å»ý¹°µþ¸²´Ù¹ß½Å°æº´(Áõ)
  • naturally toxic plant
    ÀÚ¿¬µ¶¼º½Ä¹°
  • potentially toxic compound
    ÀáÀçµ¶¼º¹°Áú
  • streptococcal toxic shock syndrome
    »ç½½¾Ë±Õµ¶¼º¼îÅ©ÁõÈıº, ¿¬¼â±¸±Õµ¶¼º¼îÅ©ÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polyneuropathy neuropathy
    ½Å»ý¹°µþ¸²¿©·¯½Å°æº´Áõ, ½Å»ý¹°µþ¸²´Ù¹ß½Å°æº´Áõ
  • polyneuropathy
    ¿©·¯½Å°æº´Áõ, ´Ù¹ß½Å°æº´Áõ
  • paraneoplastic polyneuropathy
    ½Å»ý¹°µþ¸²¿©·¯½Å°æº´Áõ, Á¾¾çµþ¸²´Ù¹ß½Å°æº´Áõ
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
  • toxic erythema
    Áßµ¶È«¹Ý
  • toxic nodule
    µ¶¼º°áÀý
  • toxic epidermal necrolysis
    µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ
  • toxic substance
    µ¶¼º¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polyneuropathy
    ´Ù¹ß½Å°æº´Áõ, ¿©·¯½Å°æº´Áõ
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
  • toxic alopecia
    µ¶¼ºÅ»¸ðÁõ
  • toxic amaurosis
    Áßµ¶Èæ¾Ï½Ã
  • toxic amblyopia
    µ¶¼º¾à½Ã
  • toxic atrophy
    Áßµ¶À§Ãà
  • potentially toxic compound
    ÀáÀçµ¶¼º¹°Áú
  • toxic cardiopathy
    Áßµ¶½ÉÀ庴Áõ
  • toxic cataract
    Áßµ¶¹é³»Àå
  • toxic conjunctivitis
    µ¶¼º°á¸·¿°
  • toxic convulsion
    Áßµ¶°æ·Ã
  • toxic liver cirrhosis
    µ¶¼º°£°æÈ­(Áõ)
  • toxic deafness
    µ¶¼º³­Ã»
  • toxic delirium
    µ¶¼º¼¶¸Á
  • toxic dementia
    Áßµ¶Ä¡¸Å
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • psychosis, toxic
    µ¶¹°Á¤½Åº´, Áßµ¶Á¤½Åº´.
  • Chemosensitizing agents
    È­ÇÐÀû °¨°¢Á¦
  • H2 recepor blocking agents, for ulcers
    H2¼ö¿ëüÂ÷´ÜÁ¦(â¥é»ô÷ó´Ó¨ð¥)
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • arsenical polyneuropathy
    ºñ¼Ò(¼º) ´Ù¹ß¼º ½Å°æº´Áõ.
  • polyneuropathy
    ´Ù¹ß½Å°æº´Áõ.
  • polyneuropathy
    ´Ù¹ß½Å°æº´Áõ(ÒýÛ¡ãêÌèÜ»ñø)
  • porphyric polyneuropathy
    Æ÷¸£ÇǸ°¼º ´Ù¹ß½Å°æº´Áõ.
  • porphyric polyneuropathy
    Æ÷¸£ÇǸ°¼º ´Ù¹ß½Å°æº´Áõ(¡­àõ ÒýÛ¡ãêÌèÜ»ñø)
  • relapsing polyneuropathy
    Àç¹ß¼º ´Ù¹ß½Å°æº´Áõ(¡­ÒýÛ¡ãêÌèÜ»ñø).
  • relapsing polyneuropathy
    Àç¹ß¼º ´Ù¹ß½Å°æº´Áõ(¡­ÒýÛ¡ãêÌèÜ»ñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • jaundice due to biliary stasis
    ´ãÁó¿ïü¼º Ȳ´Þ(ÓÅñðê¦ôòàõüÜÓ¸).
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • biologic agents
    »ý¹°ÇÐÀûÁ¦Á¦
  • eaton agents
    ÀÌÆ° º´¿øÃ¼
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • law for control of poisonous and powerful agents
    µ¶±Ø¹°Ãëü¹ý(ËÄË»ËŅ̬̃ ËÑ).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • proteolytic agents
    ´Ü¹éºÐÇØÁ¦(¡­ÝÂú°ð¥).
  • skin protective agents
    ÇǺκ¸È£Á¦.
  • skin test agents
    ÇǺιÝÀÀ¾à(ù«Ý±Úãëëå·).
  • spermicidal agents
    »ìÁ¤Á¦(߯ïñð¥).
  • alcoholic polyneuropathy
    ¾ËÄڿüº ´Ù¹ß (¼º)½Å°æº´Áõ(ÒýÛ¡àõãêÌèÜ»ñø).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • psychotropic agents
    Á¤½ÅÀÛ¿ë¾à(ïñãêíÂéÄå·)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nodular toxic goiter
    °áÀý¼ºÁßµ¶¼º°©»ó¼±Á¾
  • toxic
    µ¶¼ºÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DSPN distal sensory polyneuropathy; distal symmetrical polyneuropathy
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
OHA Oral Hypoglycemic Agents
CTA Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti...
d/t due to
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DUE DNA unwinding element
DUE Drug usage evaluation
CWA Chemical warfare agents
DBA Dentin bonding agents
DRO Differential Reinforcement of Other Behaviour
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • G62.2
    Polyneuropathy due to other toxic agents
    ±âŸ µ¶¼º¹°Áú¿¡ ÀÇÇÑ ´Ù¹ß ½Å°æº´Áõ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • jaundice due to biliary stasis
    ´ãÁó ¿ïü¼º Ȳ´Þ
  • familial amyloid polyneuropathy
    °¡Á·¼º ¾Æ¹Ð·ÎÀÌµå ´Ù¹ß ½Å°æº´Áõ
  • polyneuropathy
    ´Ù¹ß¼º ½Å°æ º´º¯, ´Ù¹ß¼º ½Å°æº´Áõ, ´Ù¹ß ½Å°æº´Áõ
    ¿©·¯ °³ÀÇ ½Å°æÀ» ÀÌȯÇÏ´Â ÁúȯÀ¸·Î¼­ º¸Åë ¾çÃø¼ºÀÌ°í ¹Ì¸¸¼ºÀÌ´Ù.
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
  • allergic-toxic contact stomatitis
    ¾Ë·¯Áö-µ¶¼º Á¢ÃË ±¸³»¿°
  • nodular toxic goiter
    °áÀý¼º Áßµ¶¼º °©»ó¼±Á¾
  • toxic action
    µ¶ ÀÛ¿ë
  • toxic amblyopia
    Áßµ¶ ¾à½Ã
  • toxic damage
    µ¶¼º ¼Õ»ó
  • toxic dyspepsia
    Áßµ¶¼º ¼ÒÈ­ ºÒ·®
  • toxic effect curve
    µ¶¼º °î¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
due date The estimated calendar date when a baby will be born, the date the baby is due to be born. It is also called the estimated date of confinement (EDC).
(12 Dec 1998)
dystonia, focal, due to blepharospasm The second most common focal dystonia, the involuntary, forcible closure of the eyelids. The first symptoms may be uncontrollable blinking. Only one eye may be affected initially, but eventually both eyes are usually involved. The spasms may leave the eyelids completely closed causing functional blindness even though the eyes and vision are normal.
(12 Dec 1998)
dystonia, focal, due to torticollis Spasmodic torticollis, or torticollis, is the most common of the focal dystonias. In torticollis, the muscles in the neck that control the position of the head are affected, causing the head to twist and turn to one side. In addition, the head may be pulled forward or backward.
(12 Dec 1998)
thrombotic disease due to protein c deficiency Protein C is a protein in plasma that enters into the cascade of biochemical events leading to the formation of a clot. Deficiency of protein c results in thrombotic (clotting) disease and excess platelets with recurrent thrombophlebitis (inflammation of the vein that occurs when a clot forms). The clot can break loose and travel through the blood stream (thromboembolism) to the lungs causing a pulmonary embolism, brain causing a stroke (cerebrovascular accident), heart causing an early heart attack, skin causing what in the newborn is called neonatal purpura fulminans, the adrenal gland causing haemorrhage with abdominal pain, abnormally low blood pressure (hypotension), and salt loss. Protein c deficiency is due to possession of one gene (heterozygosity) in chromosome band 2q13-14. The possession of two such genes (homozygosity) is usually lethal.
(12 Dec 1998)
acute demyelinating polyneuropathy <neurology> A neurologic condition.
Synonym: Guillain-Barre syndrome.
Origin: Gr. Pathos = disease
(27 Sep 1997)
acute inflammatory polyneuropathy <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin.
The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months.
Synonym: Guillain-Barre syndrome
(12 Jul 2000)
alcoholic polyneuropathy <neurology> A disorder that occurs secondary to the damage to nerve cells from habitual alcohol abuse.
The effects of alcoholic polyneuropathy may be due in part to the direct toxic effect alcohol has on nervous tissue in combination with specific nutritional deficiencies (for example B1 or thiamin deficiency and B12 deficiency).
Common symptoms include sensory changes, numbness, tingling, muscle weakness, muscle cramps, heat intolerance, impotence, difficulty urinating, swallowing difficulty, speech impairment, diarrhoea and constipation.
Origin: Gr. Pathos = disease
(27 Sep 1997)
arsenical polyneuropathy An axon loss polyneuropathy that results from subacute or chronic arsenic poisoning; almost always preceded by gastrointestinal symptoms; one of the heavy metal neuropathies.
(05 Mar 2000)
axonal polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
buckthorn polyneuropathy Ascending polyneuropathy resulting from ingestion of the fruit of Karwinskia humboldtiana.
(05 Mar 2000)
chronic inflammatory demyelinating polyneuropathy An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone.
(05 Mar 2000)
chronic inflammatory polyneuropathy <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response.
The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable.
Origin: Gr. Pathos = disease
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • toxic
    À¯µ¶ÇÑ
  • toxic
    (Áß)µ¶ÀÇ
  • due
    Á¤´çÇÑ,-¿¡ ÀÇÇÑ,Á¤È®È÷
  • due
    ÀÀ´çÄ¡·¯¾ßÇÒ;ÀÀ´ç;¿¡ µ¹¿©¾ßÇÒ;ÇÒ ¿¹Á¤ÀÎ;´ç¿¬ÇÒ;Á¤½ÄÀ¸·Î;¶§°¡ ¿À¸é;¸¶¶¥È÷;¼¼±Ý
  • due bill
    Â÷¿ë Áõ¼­
  • due date
    ¾îÀ½ÀÇ ¸¸±âÀÏ
  • due process
    (¹ý)Á¤´çÇÑ ¹ýÀÇ ÀýÂ÷(¹Ì±¹ Çå¹ý Á¦ 5Á¶,Á¦ 14Á¶)
  • postage due
    ¿ìÆí ¿ä±Ý ºÎÁ·
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á